Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Moody’s Downgrades AstraZeneca to A2 as Loses Patent Protection

Don't Miss Out —
Follow us on:

April 11 (Bloomberg) -- AstraZeneca Plc’s long-term senior unsecured debt rating was cut by Moody’s Investors Service to A2 from A1 on concern that earnings and sales will be hurt as it loses patent protection on some of its best-selling medicines.

Moody’s left the short-term rating unchanged at Prime-1 with a stable outlook. AstraZeneca has maintained a “very strong liquidity profile” with cash and equivalents of $7.7 billion at the end of 2012 and long-term committed bank facilities of $3 billion, it said in a statement. The company has 5.9 billion pounds of debt outstanding, according to data compiled by Bloomberg.

AstraZeneca, the U.K.’s second-biggest drugmaker, will soon lose patent protection on blockbusters such as the cholesterol treatment Crestor, which had sales of $6.3 billion last year. Chief Executive Officer Pascal Soriot has said he wants to focus on product licensing and the company’s own drug-development efforts to return to growth.

Any improvement in AstraZeneca’s “currently modest pipeline will take time to materialize” and sales from recently launched drugs won’t be able to offset the revenue decline, Marie Fischer-Sabatie, senior credit officer and lead analyst for AstraZeneca at Moody’s, said in the statement today.

Standard & Poor’s revised its outlook on the company’s debt on April 8 to negative from stable, citing a “strong revenue decline” that could ultimately lead to a downgrade.

To contact the reporter on this story: Allison Connolly in London at aconnolly4@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.